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Strengths and limitations of this study
 ► The first study to systematically assess visually guid-
ed reaching in patients with cognitive impairment.
 ► Includes a simple tablet- based task (lateral reaching) 
that could be readily translated to clinical settings to 
assess the presence of peripheral misreaching.
 ► Case–control statistical tests of deficit are inherently 
low powered, subtle deficits of misreaching may not 
be detected at the level of individual patients.
AbStrACt
Introduction Recent evidence has implicated the 
precuneus of the medial parietal lobe as one of the first 
brain areas to show pathological changes in Alzheimer’s 
disease (AD). Damage to the precuneus through focal 
brain injury is associated with impaired visually guided 
reaching, particularly for objects in peripheral vision. This 
raises the hypothesis that peripheral misreaching may be 
detectable in patients with prodromal AD. The aim of this 
study is to assess the frequency and severity of peripheral 
misreaching in patients with mild cognitive impairment 
(MCI) and AD.
Methods and analysis Patients presenting with amnestic 
MCI, mild- to- moderate AD and healthy older- adult 
controls will be tested (target N=24 per group). Peripheral 
misreaching will be assessed using two set- ups: a 
tablet- based task of lateral reaching and motion- tracked 
radial reaching (in depth). There are two versions of each 
task, where participants can look directly at targets (free 
reaching), and when they must maintain central fixation 
(peripheral reaching). All tasks will be conducted first on 
their dominant, and then their non- dominant side. For each 
combination of task and side, a Peripheral Misreaching 
Index (PMI) is then calculated as the increase in absolute 
reaching error between free and peripheral reaching. 
Each patient will be classified as showing peripheral 
misreaching if their PMI is significantly abnormal, by 
comparison to control performance on either side of space. 
We will then test whether the frequency of peripheral 
misreaching exceeds the chance level in each patient 
group and compare the overall severity of misreaching 
between groups.
Ethics and dissemination Ethical approval was provided 
by the NHS East of England, Cambridge Central Research 
Ethics Committee (REC 19/EE/0170). The results of this 
study will be published in a peer- reviewed journal and 
presented at academic conferences.
IntroduCtIon
The pathophysiological cascade that leads 
to Alzheimer’s disease (AD) can begin up 
to 20 years before the onset of cognitive 
problems in both autosomal and sporadic 
AD.1–5 In dominant and early- onset cases, 
there is evidence that the precuneus is one 
of the earliest regions to be affected.5 6 Focal 
damage in and around this brain area is 
known to be associated with deficits of visu-
ally guided action.7 One example of such a 
condition is optic ataxia, an impairment of 
misreaching typically reflected in peripheral 
vision.8 9 Patients with optic ataxia do not 
often report this symptom and it is rarely 
assessed in clinical settings, and it can there-
fore go undetected.10 The changes observed 
in the precuneus in prodromal AD, and 
the link between the precuneus and optic 
ataxia, raise the hypothesis that optic ataxic 
misreaching may be detectable in patients 
with prodromal AD.
 Specific hypothesis
The hypothesis that peripheral misreaching 
is a feature of AD predicts that individual 
patients with AD, and possibly those with mild 
cognitive impairment (MCI), will show an 
abnormally large inflation of reaching errors 
when aiming for targets in peripheral vision, 
as compared with targets in free vision. At a 
group level, patients with AD and, to a lesser 
extent, patients with MCI will show signifi-
cantly greater peripheral misreaching than 
healthy controls (HCs).
MEthodS
Study setting
The study is a collaboration between clini-
cians and University staff at the University 
of Edinburgh (UoE) and University of East 
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Anglia (UEA). The details of recruitment and site infor-
mation can be found in the online supplementary mate-
rials. Data collection for this study began on 03 October 
2019 and 8 of 48 patients have taken part. Data for HCs 
have already been collected.
Participants
Patients with a diagnosis of amnestic MCI or typical 
(amnestic) mild- to- moderate AD will be invited to take 
part. Mild- to- moderate AD will be defined by a score of 
at least 50 in the most recent administration of Adden-
brooke’s Cognitive Examination (ACE- III).11 If there is 
no recorded ACE- III score, clinical opinion of patient’s 
condition will be used to assess eligibility.
Older adults without any known neurological disorders 
will be tested as an HC group. To achieve our target of 24 
full datasets per group (Power considerations section), we 
plan to test up to 30 participants in each group, allowing 
for possible withdrawals.
Inclusion criteria
For all participant groups, the ability to give informed 
consent is the initial inclusion criterion. Additional inclu-
sion criteria are then applied to each group.
Control group inclusion criteria:
 ► Aged 50–75. (NB. The age- range for controls is 
targeted at the expected age range for patients, but the 
allowable range of ages for patients is wider than this, 
in order not to restrict recruitment unnecessarily.)
 ► No reported neurological or neurodegenerative 
conditions.
MCI group inclusion criteria:
 ► Aged 45–85.
 ► Clinical diagnosis of MCI with an amnestic pattern 
of presentation. This includes an observed deficit 
on cognitive/neuropsychological testing suggesting 
amnestic and visuospatial profile deficit, low β-amy-
loid, elevated phosphorylated Tau, regional atrophy 
on MR brain imaging and/or regional perfusion 
changes on HMPAO- SPECT.
AD group inclusion criteria:
 ► Aged 45–85.
 ► Clinical diagnosis of AD.
Exclusion criteria
For all participant groups, the following exclusion criteria 
are applied:
 ► Significant difficulty communicating or under-
standing instructions in English.
 ► Significant, uncorrected visual impairment (eg, cata-
ract, macular degeneration, scotoma, amblyopia and 
strabismus).
 ► Conditions that could interfere with smooth hand 
movements (eg, ataxia, essential tremor and severe 
arthritis).
 ► Prior history of stroke or TIA.
 ► Clinical features suggested of Lewy body pathology 
(eg, visual hallucinations or REM sleep disorder).
Public and patient involvement
Patients with MCI or AD and their careers were involved 
in the early stages of planning and development. A focus 
group was held at the Anne Rowling Clinic in Edinburgh 
where patients and carers had the opportunity to try out 
prototypes of the tablet- based reaching task and provide 
feedback on task design. This feedback was used to opti-
mise the final task for patient accessibility and clarity.
tasks
Two different set- ups will be used to assess peripheral 
reaching: a tablet- based assessment of reaching in the 
frontoparallel plane (lateral reaching), and a motion- 
tracking assessment of reaching in radial depth (radial 
reaching). Participants will complete two versions of each 
reaching task: a version in which participants look directly 
at targets before reaching to them (free reaching); and a 
version where central fixation is maintained (peripheral 
reaching). Any general factors affecting motor accuracy 
should influence both free and peripheral reaching, so 
we will treat the free reaching condition as a baseline 
condition, to be subtracted from peripheral reaching 
performance, to isolate the specific increase in error due 
to peripheral target presentation.12 The critical outcome 
measure is therefore the inflation of absolute reaching 
error in peripheral reaching relative to free reaching.
Before testing, the participant’s dominant writing hand 
is identified (by self- report). All tasks are completed first 
on the dominant side, using the dominant hand, followed 
by the non- dominant side and hand. Lateral reaching is 
completed first, followed by radial reaching. All tasks are 
performed in the same order for all participants.
Lateral reaching tasks
Stimuli and apparatus
Stimuli are presented on an HP Pavillion ×360 touch 
screen (active display 310×175 mm, resolution 1920×1080 
pixels). Tasks are controlled by a custom programme 
written in OpenSesame V.3.2.8 Kafkesque Koffka.13 Partici-
pants are seated 40 cm away from the screen which is posi-
tioned with either the right edge of the screen aligned 
to their midline (left- sided reaching, figure 1A) or the 
left edge (right- sided reaching, figure 1B). A start box 
(white rectangle, 2°×2°, 13.96×13.96 mm) is drawn at the 
centre edge (right or left) of the screen, aligned to partic-
ipant’s midpoint. In some tasks (detailed below) a white 
fixation cross is present (1°×1°, 6.98×6.98 mm), located 
34.9 mm (5°) directly above the start box. Targets are 
white circles (diameter=2°, 13.96 mm) presented along 
radial spokes at 28°, 33° and 38° to the left (figure 1A) or 
right (figure 1B) of fixation. The experimenter sits across 
the table and monitors eye movements directly.
 Free reaching
For the first block in the lateral reaching task participants 
are not required to fixate, therefore, the fixation cross is 
absent.
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Figure 1 Nine target positions during the lateral reaching 
task for left (A) and right (B) hand sides, At a viewing distance 
of 40 cm targets are presented at approximately 28°, 33° and 
38° of eccentricity.
Participants initiate a trial by pressing and holding 
down the start box, which disappears at touch. At this 
point, they may search the screen for a target. After a 
short delay (250–750 ms, randomised 100 ms intervals), a 
target appears at one of nine possible locations. As soon 
as the target appears, participants look at it and make 
one smooth reach to try to touch the target. The target 
remains on the screen until a touch is recorded at any 
location, and then the target disappears and a short beep 
(100 ms, 440 Hz) is played. The validity of the trial is then 
coded by the experimenter using a keyboard; ‘y’—valid 
trial, ‘e’—the participant did not move their eyes to the 
target, ‘v’—invalid trial, and the start box reappears to 
begin another trial.
If the experimenter presses ‘e’ or ‘v’ that trial is 
repeated until a valid trial is recorded. The block ends 
after a minimum of 27 valid trials (3 per target location), 
or after 50 valid and ‘no eye- movement’ trials.
 Visual detection
This is a simple check to confirm that the participant 
is capable of detecting the targets when presented in 
peripheral vision, to be allowed for a meaningful test of 
peripheral reaching (Peripheral reaching section).
Throughout each trial the participant must gaze at 
the fixation cross. They initiate the trial by pressing and 
holding down the start box, which disappears when 
touched. In order to aid the maintenance of fixation, the 
fixation cross cycles between white and red at the screen 
refresh rate (60 Hz). After a short delay (250–750 ms), a 
target can appear at one of the nine locations for 1 s, or no 
target appears. This is followed by a short beep (100 ms, 
440 Hz) to indicate the end of the trial. The participant 
must verbally report whether or not a target was seen in 
that interval. The experimenter records the response 
using the keyboard (‘y’—yes, ‘n’—no). If the participant 
makes an eye movement, the experimenter presses ‘e’ 
and the trial is repeated. The block ends after 15 valid 
(no eye- movement) trials, one for each of the nine target 
locations, and six catch trials with no target.
To progress to the peripheral reaching task, partic-
ipants are required to detect at least 6/9 targets and 
correctly rejects at least 3/6 catch trials. Otherwise, 
testing is discontinued on that side of space.
Peripheral reaching
For peripheral reaching, participants are required to 
gaze at the fixation cross throughout each trial. A trial 
begins by pressing and holding down the start box. When 
touched, the start box disappears and the fixation cross 
cycles between white and red (at a rate of 60 Hz) until 
the trial ends. After a short delay (250–750 ms) a target 
appears at one of nine locations. While maintaining 
fixation, participants make one smooth reaching move-
ment to try to touch the target. The target remains on 
the screen until a touch is recorded at any location, and 
a short beep is played once the target disappears. The 
experimenter then records the validity of the trial; ‘y’—
valid, ‘e’—participant moved their eyes away from fixa-
tion, ‘v’—invalid trial.
Invalid (‘e’ or ‘v’) trials are repeated until a valid trial 
is recorded. The block ends after a minimum of 27 valid 
trials (three per target location), or after 50 valid and 
‘eye- movement’ trials.
 Radial reaching tasks
Stimulus and Apparatus
An infrared motion- tracking camera (Optotrak Certus, 
Northern Digital) is used to track the reaching move-
ment. Infrared- emitting diodes (IREDs) are taped to the 
tip of the right and left index fingers of each participant to 
track the reach in each hand. The Optotrak samples the 
IRED’s 3D position at 100 Hz throughout each 2000 ms 
trial. The task is controlled by custom software written 
in LabView (National Instruments) programming envi-
ronment. (The stimuli and apparatus reported here are 
specific to UoE. At the second site, UEA, motion tracking 
was performed by using a Qualisys AB system (Gothen-
burg, Sweden). Targets are green LEDs (diameter=0.68°, 
6 mm). The experiment is presented on a grey table 
(100×100 cm) and the experiment is run through Psycho-
physics Toolbox14 in MATLAB (Mathworks, USA).)
Participants are seated with their head placed in a 
chin- rest in line with the middle of the display. Stimuli 
are back projected via a mirror onto a screen (1000 mm 
wide × 750 mm deep) that lies flat in- front of the partic-
ipant. A webcam is placed on the screen 50 cm directly 
in- front of the participant, as a fixation point. The live 
webcam image feeds into a separate laptop, allowing 
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Figure 2 Target positions during the radial reaching task 
shown here on both the right- hand and left- hand sides, at 
11.4°, 22.6°, 33.4° and 43.6° from fixation. The start button 
is positioned at the bottom of the screen 40 cm away from 
central fixation. A webcam is placed at the point of central 
fixation (midpoint).
experimenter to monitor gaze. A start button is aligned to 
the centre of the screen, positioned 10 cm in- front of the 
participant, 40 cm away from fixation (figure 2). Targets 
are white circles (diameter=1.60°, 13.96 mm) presented 
at four eccentric locations (11.4°, 22.6°, 33.4° and 43.6° 
away from centre) on each side (figure 2).
Calibration
A calibration procedure is carried out before the reaching 
tasks to record the IRED position at the actual target loca-
tion. A target is displayed at one target location and the 
participant is instructed to cover it completely with their 
reaching finger. Once the target is covered, the experi-
menter presses the start button and the finger location 
is recorded for 2000 ms. A beep plays after 2000 ms, indi-
cating that the participant can move their hand away 
from the target position. Another target appears at the 
next location and the same procedure is repeated. Cali-
bration is run using the ipsilateral hand for four targets 
on the left side and four on the right.
Free reaching
Participants initiate a trial by pressing and holding down 
the start button. As soon as they push the button down, 
participants may look around the screen for a target. 
After 250–750 ms a target appears, participants then look 
directly at the target and reach to touch the target in 
one smooth movement. Optotrak recording is initiated 
simultaneously with target appearance, and the target 
disappearance is the simultaneous with the end of the 
recording after 2000 ms. When the target disappears a 
short beep (100 ms, 440 Hz) plays, the participant leaves 
their finger at its landing position until they hear the 
beep. After the trial, the experimenter codes the trial 
validity with a key- press; ‘Return’—valid, ‘F1’—no eye- 
movement, ‘Esc’—invalid trial. If an invalid trial (‘F1’ or 
‘Esc’) is coded the trial gets recycled to the end of the 
shuffled trial.
The block ends once 28 valid trials (7 per target 
location) are recorded, or after 50 valid and ‘no eye- 
movement’ trials.
 Peripheral reaching
To assess reaching accuracy in the periphery participants 
are required to look directly at central fixation (the 
webcam) throughout each trial. Participants initiate a 
trial by pressing and holding down the start button. After 
250–750 ms a target appears. While maintaining gaze 
on the webcam participants make one smooth reaching 
movement to try to touch the target. After the reach, 
participants leave their finger at its landing position 
until a short beep (100 ms, 440 Hz). The target remains 
on screen for 2000 ms after the trial begins. The motion- 
tracker records the reach throughout the 2000 ms trial. 
At the end of the trial, the experimenter codes trial 
validity; ‘Return’—valid trial, ‘F1’—eye movement during 
trial, ‘Esc’—invalid trial. If an invalid trial (‘F1, ‘Esc’) is 
recorded then the trial is recycled to the end of the shuf-
fled trial list.
The block ends after 28 valid trials (7 per target loca-
tion) are recorded, or after 50 valid and ‘eye- movement’ 
trials.
AnAlySIS PlAn
 lateral reaching task
For the critical analyses, a single measure of reaching 
accuracy is taken for each participant, for each combi-
nation of viewing condition (free, peripheral) and side 
(non- dominant, dominant). For each response, the abso-
lute error (in mm, x- axis and y- axis) is recorded as the 
distance of the reach endpoint from the target midpoint. 
The median absolute error is then calculated for each 
target eccentricity, across responses to the three targets 
at that eccentricity, for each combination of viewing 
condition and side. The average absolute error is then 
calculated as the mean of the medians for the three eccen-
tricities, to give the single measure of reaching accuracy 
for each viewing condition at each side.
For the comparison of individual patients against 
control performance, the data are further compressed 
to a single index of performance per side, by subtracting 
reaching accuracy in the free vision condition from the 
peripheral condition. We call this value the Peripheral 
Misreaching Index (PMI).
Analysis of single-case deficits
We will screen the control group for outliers that might 
suggest abnormalities, as such values would reduce the 
(already low, see figure 3) power to detect single- case 
deficits. We will use a robust method of outlier detection 
based on the median absolute deviation (MAD). The 
MAD can be multiplied by the consistency constant 1.4826 
to estimate the SD, assuming a normal distribution. Each 
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Figure 3 (A) Relation between control sample size and 
power to detect a single- case deficit in a one- tailed test, for 
different size of deficit (D, expressed as SD of control mean), 
(B) relation between deficit size (D) and power to detect a 
single- case deficit, given a control sample size of 24, for 
adjusted and unadjusted alpha criteria.
control participant’s PMI can be expressed a modified 
Z- score (Z′) by subtracting the group median, divided by 
the MAD *1.4826. If Z′ exceeds 2.5, that participant will 
be excluded, and replaced. Our simulations suggest that, 
for a group size of 24, we would expect to exclude (on 
average)<1 participant (~0.67) by this criterion.
We will next assess, for each side, whether the PMI of 
controls is related to age or sex, by computing Pearson’s 
correlations. If the correlation is ≥0.3 on either side, then 
that variable will be included as a covariate in the subse-
quent case–control comparisons for both sides.
Case–control comparisons will then be run to compare 
each patient’s PMI against control performance. These 
comparisons will be based on Crawford and Howell's15 
modified t- test; or, if covariates are included, we will use 
the updated test of deficit.16 The individual tests will be 
one- tailed, with an alpha level set to 0.025, in order to 
constrain per- patient alpha level (across the two sides) 
to o.05. If a patient shows a deficit on either side that 
would meet the unadjusted criterion (0.05), but not 
the adjusted criterion (0.025), they will be classified as 
showing borderline peripheral misreaching.
Finally, a binomial test will test whether the rate of 
observed peripheral misreaching exceeds the rate 
expected by chance (ie, the per- patient adjusted alpha 
level of 0.05). A significant outcome (p<0.05) for either 
patient group will indicate that peripheral misreaching 
is a feature of this patient group. The observed rate of 
peripheral misreaching will provide an estimate of how 
common it is. We will run a further analysis including 
borderline cases and compare the rate of peripheral 
misreaching in each patient group against the appro-
priate chance level of 0.10.
 Group-level analysis
The case–control approach will be complemented by a 
group- level ANOVA of reaching accuracy, as measured by 
the PMI, with the between- subject factor of group (HC, 
MCI, AD) and the within- subject factor of side (non- 
dominant, dominant). This analysis will test whether the 
average severity of peripheral misreaching in each patient 
group significantly exceeds that observed in HCs.
Exploratory analyses
Any lateralisation that occurs in MCI/AD is likely to be 
limited, therefore, any impairment in peripheral reaching 
may be similarly non- lateralised. An average PMI (across 
both sides) will therefore be calculated to assess periph-
eral reaching ability overall. More detailed analyses will 
be run with a between- subject factor of group and within- 
subject factors of side, eccentricity and viewing condi-
tion. These analyses will be conducted using dependent 
variables of absolute reaching error, directional (signed) 
reaching error, reaction time and movement time. The 
expectation is that peripheral misreaching will manifest 
as a fixation- directed bias, which is exacerbated at higher 
eccentricities significantly more so in patient groups than 
in age- matched controls.
radial reaching task
IRED speed is used to determine onset and offset of the 
reaching movement. Movement onset is defined as the 
first frame in which the IRED’s speed exceeds 50 mm/s 
(and maintains that speed for up to 100 ms). Movement 
offset is defined as the first subsequent frame in which 
IRED speed falls below 50 mm/s. The landing position 
of the movement is defined by the x- coordinate and y- co-
ordinate in the final frame of the movement and will 
be recorded as errors relative to true target locations 
recorded during calibration for each participant.
An initial analysis of PMI for the radial reaching task 
will be performed, restricted to the two most eccentric 
target positions (33.4° and 43.6°). Case–control compar-
isons follow the plan for the lateral reaching task (Anal-
ysis of single case deficits section), to estimate the rates 
of peripheral misreaching, and borderline peripheral 
misreaching, in the two patient groups. Due to different 
experimental set- ups between the two test sites (UoE, 
UEA), each patient will be referenced to the same- site 
control data for case–control comparisons.
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A group level ANOVA of PMI, restricted to the two most 
eccentric target positions, will similarly follow the plan 
for lateral reaching (Group- level analysis section). We 
will include site (UoE, UEA) as an additional covariate. 
Subsequent, more detailed analyses will also follow the 
plan for lateral reaching (Group- level analysis section). 
Since motion tracking also provides kinematic variables 
on reaching trajectories, we also aim to examine the 
dependent variables peak speed and time to peak speed, 
normalised time after peak speed until reach endpoint 
and number of secondary movements.
Power considerations
The target sample sizes (N=24 per group) are based on 
power considerations related to the main inferential anal-
yses, the case–control comparisons and binomial tests of 
rates of peripheral misreaching deficits for the lateral 
reaching task.
The control sample size of 24 will provide close to 
the maximum power for case–control tests of deficit 
(figure 3A). Note that high power for these compari-
sons is inherently unachievable unless the deficit being 
tested for is very large. We do not know how large any 
misreaching deficits may be in our patient groups, but 
our control sample size will provide close to the maximum 
achievable power to detect them if they exist. Figure 3B 
illustrates more fully the relationship between deficit size 
(D) and power, for the adjusted alpha level (0.025) and 
unadjusted alpha level (0.05) by which we will determine 
peripheral misreaching deficits and borderline cases, 
respectively, (Analysis of single case deficits section).
The main hypothesis is that peripheral misreaching 
will be found in a significant proportion of patients with 
AD and MCI. For one- sample binomial test to determine 
whether the observed rate of peripheral misreaching 
exceeds the chance level of 0.05, a sample size of 24 has 
>0.9 power. Provided that the true population proportion 
is at least 0.2 (1 in 5). This is appropriate to our aims, 
since peripheral misreaching would be of limited signifi-
cance in these clinical populations if its prevalence were 
less than 1 in 5.
EthICS And dISSEMInAtIon
This protocol was approved by UK Health Research 
Authority, by the East of England, Cambridge Central 
Research Ethics Committee on 13 June 2019 (REC refer-
ence 19/EE/0170).
All patients will provide informed consent, highlighting 
the voluntary nature of the study and their right to with-
draw. If there is any doubt about the ability of the patient 
to provide informed consent, then this patient will not be 
recruited. There are no direct risks associated with taking 
part.
Careful consideration will be taken to maintain 
patient’s confidentially. After consent is provided, an 
anonymous code will be assigned to each patient. Some 
patient details, such as CHI number, age, gender and 
time of diagnosis, will need to be accessed by the research 
team, these details will be stored alongside patient code 
in a password- protected document.
At the end of the study, a lay summary of results will 
be provided to patients who have expressed a further 
interest. Project results will be made publicly available on 
the Open Science Framework (https:// osf. io/ bxnqs/) 
within 3 months after study end date (30 June 2020). 
Alongside this, we plan to publish the results of this 
protocol will be published in a peer- reviewed journal and 
presented at academic conferences.
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